NCT04720157

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2021-06-09Est. Completion: 2025-01-13

Enrollment target: 1,140 participants

Locations

Mayo Clinic - Arizona Mayo Clinic Hospital, Scottsdale, Arizona, United States
Mayo Clinic Arizona, Scottsdale, Arizona, United States
University of California San Diego - Moores Cancer Center, La Jolla, California, United States
VA Greater LA Healthcare System, Los Angeles, California, United States
University of California LA, Los Angeles, California, United States
St. Joseph Hospital, Orange, California, United States
Univ Cali Irvine ALS Neuromuscular, Orange, California, United States
VA Palo Alto Health Care System, Palo Alto, California, United States
Stanford University Medical Center, Palo Alto, California, United States
Sansum Clinic, Santa Barbara, California, United States
Providence Saint Johns Health Ctr, Santa Monica, California, United States
Univ Of Color Anschutz Med Center, Aurora, Colorado, United States
Rocky Mountain Cancer Centers, Denver, Colorado, United States
Hartford Hospital, Hartford, Connecticut, United States
Georgetown University-Lombardi Cancer Center, Washington D.C., District of Columbia, United States

Prostate Cancer

The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in…

Harbin, ChinaEst. completion Jun 2026

Localised Prostate Cancer

The goal of this randomised clinical trial is to assess whether personalised treatment counselling can improve the decis…

Multiple LocationsEst. completion Nov 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.